Student Work

CHARACTERIZATION OF NOVEL NUCLEOSIDE ANALOG DRUGS AGAINST HSV-1 INFECTION

Public

Downloadable Content

open in viewer

Infection with Herpes Simplex Virus-1 (HSV-1) is common in humans, and can lead to severe symptoms if drug resistance occurs. This project aimed to select a novel nucleoside analog showing potential as an HSV-1 antiviral therapy, and to begin to characterize its mechanism of action. Using plaque reduction and MTS assays, compound MBX 2168 was identified as a potential candidate with strong antiviral activity and low toxicity. Mutational studies of 3 viral kinases and kinetic studies of human 2-deoxyguanosine kinase (dGK) suggest that MBX 2168 is not initially phosphorylated by those viral kinases and is not phosphorylated by human dGK. Sequence analysis and molecular modeling of an HSV-1 strain resistant to MBX 2168 suggest that the drug works by inhibiting HSV-1 DNA synthesis.

  • This report represents the work of one or more WPI undergraduate students submitted to the faculty as evidence of completion of a degree requirement. WPI routinely publishes these reports on its website without editorial or peer review.
Creator
Contributors
Publisher
Identifier
  • E-project-042612-131319
Advisor
Year
  • 2012
Sponsor
Date created
  • 2012-04-26
Resource type
Major
Rights statement
Last modified
  • 2023-09-27

Relations

In Collection:

Items

Items

Permanent link to this page: https://digital.wpi.edu/show/0g354h16n